Log In | Register
The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer.
FDA: Include warnings on risk for class of prostate cancer drugs
Seeded on Fri Oct 22, 2010 1:52 PM EDT
Article Source: Food and Drug Administration Press Releases- Enjoy this article? Help vote it up the 'Vine.
- Public Discussion (0)
You're in Easy Mode. If you prefer, you can use XHTML Mode instead. |
As a new user, you may notice a few temporary content restrictions. Click here for more info.
